biological source
rabbit
conjugate
unconjugated
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
species reactivity
mouse
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable, immunohistochemistry: suitable, immunoprecipitation (IP): suitable, neutralization: suitable, western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Quality Level
Gene Information
mouse ... Ifnb1(15977)
正在寻找类似产品? 访问 产品对比指南
Immunogen
Mouse IgG, whole molecule.
Application
Cytopathic effect inhibition assay: 2 x 10E5 neutralization units per mL of antiserum. One neutralization unit is the amount of antiserum required to neutralize 1 unit of mouse IFN-beta. This material is prepared specifically for effective neutralization of mouse IFN-beta.
Western blot (1:500) The antibody reacts with a 19kDa band coresponding to Mu-IFN-beta. Protocol below:
1. Put protein (approx 50ng) in blocking solution for 30-60 min RT
2. Add Primary antibody (1:500) to blocking solution
3. Agitate membrane for 60 min, RT
4. Wash 3X for 5min each with PBS-Tween
5. Add secondary antibody (1:1000) after diluting in PBS-Tween
6. Gentle agitation for 60min.
7. Wash 3X for 5min each with PBS-Tween
8. Develop with reaction kit of choice
Immunoprecipitation
Immunohistochemistry
ELISA
Optimal working dilutions must be determined by end user.
Western blot (1:500) The antibody reacts with a 19kDa band coresponding to Mu-IFN-beta. Protocol below:
1. Put protein (approx 50ng) in blocking solution for 30-60 min RT
2. Add Primary antibody (1:500) to blocking solution
3. Agitate membrane for 60 min, RT
4. Wash 3X for 5min each with PBS-Tween
5. Add secondary antibody (1:1000) after diluting in PBS-Tween
6. Gentle agitation for 60min.
7. Wash 3X for 5min each with PBS-Tween
8. Develop with reaction kit of choice
Immunoprecipitation
Immunohistochemistry
ELISA
Optimal working dilutions must be determined by end user.
Detect Interferon-β using this Anti-Interferon-β Antibody validated for use in ELISA, IP, WB, IH, NEUT.
Research Category
Inflammation & Immunology
Inflammation & Immunology
Research Sub Category
Cytokines & Cytokine Receptors
Cytokines & Cytokine Receptors
Biochem/physiol Actions
Reacts with mouse Interferon beta (IFNbeta). No reactivity is seen with IFNalpha or gamma
Packaging
2x10(e4) units
Physical form
Rabbit polyclonal serum in buffer containing 0.3 M NaHCO3 and 200 mM NaCl.
Preparation Note
Maintain frozen at -20°C or below for retention of full activity, for up to 12 months. When thawing, the contents of the tube should be apportioned in separate tubes so that freezing and thawing is kept to a minimum.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品?
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Choon Kit Tang et al.
PloS one, 8(3), e60038-e60038 (2013-04-05)
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent type I interferon (IFN) inducer, was evaluated as a chemotherapeutic agent in mouse cancer models and proved to be well tolerated in human cancer clinical trials. Despite its multiple biological functions, DMXAA has not been
Anna Niewiadomska-Cimicka et al.
International journal of molecular sciences, 25(8) (2024-04-27)
Polyglutamine (polyQ)-encoding CAG repeat expansions represent a common disease-causing mutation responsible for several dominant spinocerebellar ataxias (SCAs). PolyQ-expanded SCA proteins are toxic for cerebellar neurons, with Purkinje cells (PCs) being the most vulnerable. RNA interference (RNAi) reagents targeting transcripts with
Dwijit GuhaSarkar et al.
Molecular oncology, 11(2), 180-193 (2017-01-18)
The highly invasive property of glioblastoma (GBM) cells and genetic heterogeneity are largely responsible for tumor recurrence after the current standard-of-care treatment and thus a direct cause of death. Previously, we have shown that intracranial interferon-beta (IFN-β) gene therapy by
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持